| Primary |
| Product Used For Unknown Indication |
40.0% |
| Wound Infection |
40.0% |
| Cough |
20.0% |
|
| Respiratory Gas Exchange Disorder |
50.0% |
| Vomiting |
50.0% |
|
| Secondary |
| Drug Use For Unknown Indication |
22.4% |
| Product Used For Unknown Indication |
20.0% |
| Erysipelas |
10.7% |
| Lung Disorder |
7.3% |
| Osteomyelitis |
4.3% |
| Unevaluable Event |
4.0% |
| Bronchitis |
3.8% |
| Sinusitis |
3.2% |
| Pain |
3.1% |
| Prophylaxis |
2.9% |
| Antibiotic Therapy |
2.6% |
| Device Related Infection |
2.4% |
| Pneumonia Necrotising |
2.0% |
| Pneumonia Pneumococcal |
2.0% |
| Erythrosis |
1.8% |
| Hypertension |
1.7% |
| Staphylococcal Infection |
1.7% |
| Abscess |
1.5% |
| Endocarditis |
1.3% |
| Paronychia |
1.3% |
|
| Toxic Skin Eruption |
20.3% |
| Thrombocytopenia |
8.5% |
| Acute Generalised Exanthematous Pustulosis |
7.2% |
| Agranulocytosis |
6.5% |
| Visual Field Defect |
6.5% |
| Urticaria |
5.9% |
| Renal Failure Acute |
4.6% |
| Pyrexia |
3.9% |
| Skin Exfoliation |
3.9% |
| Skin Lesion |
3.9% |
| Skin Test Negative |
3.9% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
3.3% |
| Subdural Haematoma |
3.3% |
| Toxic Epidermal Necrolysis |
3.3% |
| Diarrhoea |
2.6% |
| Pleural Haemorrhage |
2.6% |
| Pruritus |
2.6% |
| Rash Pustular |
2.6% |
| Serum Ferritin Increased |
2.6% |
| Cytolytic Hepatitis |
2.0% |
|
| Concomitant |
| Drug Use For Unknown Indication |
25.7% |
| Product Used For Unknown Indication |
14.5% |
| Hypertension |
7.2% |
| Bronchitis |
6.8% |
| Erysipelas |
5.1% |
| Pain |
4.9% |
| Prophylaxis |
4.9% |
| Ischaemic Cardiomyopathy |
3.4% |
| Hiv Infection |
3.2% |
| Sinusitis |
3.2% |
| Anaesthesia |
3.1% |
| Asthma |
2.6% |
| Diabetes Mellitus |
2.3% |
| Multiple Myeloma |
2.2% |
| Skin Infection |
2.1% |
| Hypercholesterolaemia |
1.9% |
| Infection |
1.8% |
| Anxiety |
1.7% |
| Staphylococcal Infection |
1.7% |
| Cough |
1.7% |
|
| Toxic Skin Eruption |
10.1% |
| Renal Failure Acute |
8.6% |
| Vomiting |
8.6% |
| Renal Failure |
7.2% |
| Acute Generalised Exanthematous Pustulosis |
6.5% |
| Cytolytic Hepatitis |
6.5% |
| Urticaria |
5.8% |
| Neutropenia |
5.0% |
| Hepatocellular Injury |
4.3% |
| Pyrexia |
4.3% |
| Staphylococcal Infection |
4.3% |
| Tachycardia |
4.3% |
| Sudden Death |
3.6% |
| Thrombocytopenia |
3.6% |
| Anal Cancer |
2.9% |
| Hepatitis |
2.9% |
| Osteoporosis |
2.9% |
| Rash Papular |
2.9% |
| Septic Shock |
2.9% |
| Shock Haemorrhagic |
2.9% |
|
| Interacting |
| Hypertension |
24.2% |
| Lymphangitis |
12.1% |
| Drug Use For Unknown Indication |
6.1% |
| Dyslipidaemia |
6.1% |
| Hypercholesterolaemia |
6.1% |
| Peripheral Arterial Occlusive Disease |
6.1% |
| Phlebitis |
6.1% |
| Skin Ulcer |
6.1% |
| Angina Pectoris |
3.0% |
| Arrhythmia |
3.0% |
| Atrial Fibrillation |
3.0% |
| Benign Prostatic Hyperplasia |
3.0% |
| Erysipelas |
3.0% |
| Gastric Ulcer |
3.0% |
| Myocardial Ischaemia |
3.0% |
| Pericardial Effusion |
3.0% |
| Prophylaxis |
3.0% |
|
| Pruritus |
25.0% |
| Erysipelas |
12.5% |
| Hepatitis |
12.5% |
| International Normalised Ratio Increased |
12.5% |
| Overdose |
12.5% |
| Pancytopenia |
12.5% |
| Vomiting |
12.5% |
|
